This hypothesis is supported by the results showing that PARP inhibitors were selectively toxic to LIG4-deficient melanoma and leukemia cells (this work) and that they increased DNA damage induced by radiation exposure in LIG4−/− HCT116 colon carcinoma cell line [19]. The gene discussed is LIG4; the disease is leukemia.